Omaveloxolone Capsules, 300 mg ( DrugBank: Omaveloxolone )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 18 | 脊髄小脳変性症（多系統萎縮症を除く。） | 1 |
18. 脊髄小脳変性症（多系統萎縮症を除く。）
臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02255435 (ClinicalTrials.gov) | January 2015 | 30/9/2014 | RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe | A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe) | Friedreich Ataxia | Drug: Omaveloxolone Capsules, 2.5 mg;Drug: Omaveloxolone Capsules, 5 mg;Drug: Omaveloxolone Capsules, 10 mg;Drug: Placebo;Drug: Omaveloxolone Capsules, 20 mg;Drug: Omaveloxolone Capsules, 40 mg;Drug: Omaveloxolone Capsules, 80 mg;Drug: Omaveloxolone Capsules, 160 mg;Drug: Omaveloxolone Capsules, 300 mg;Drug: Omaveloxolone Capsules, 150 mg | Reata Pharmaceuticals, Inc. | AbbVie;Friedreich's Ataxia Research Alliance | Active, not recruiting | 16 Years | 40 Years | All | 172 | Phase 2 | United States;Australia;Austria;Italy;United Kingdom;Brazil |